Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fontana — Fontana, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Sites in California: - Sutter Auburn Faith Hospital — Auburn, California
- Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- City of Hope at Irvine Lennar — Irvine, California
Phase 3 Recruiting Network
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spr…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04510597
Sites in California: - PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Keck Medicine of USC Buena Park — Buena Park, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Health System - Encinitas — Encinitas, California
Phase 3 Recruiting Industry
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carc…
Sponsor: Arcus Biosciences, Inc.
NCT ID: NCT07011719
Sites in California: - City Of Hope National Medical Center — Duarte, California
- University of California San Diego Moores Cancer Center — La Jolla, California
- UCLA Hematology Oncology - 100 Med Plaza — Los Angeles, California
- University of California San Diego Moores Cancer Center — San Diego, California
Phase 3 Recruiting Industry
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Sponsor: Xynomic Pharmaceuticals, Inc.
NCT ID: NCT03592472
Sites in California: - University of California Davis Comprehensive Cancer Center — Sacramento, California
- UCSF Helen Diller Family Comphrensive Cancer Center - Hemato — San Francisco, California
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
Phase 2 Recruiting Academic/Other
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…
Sponsor: NRG Oncology
NCT ID: NCT05327686
Sites in California: - PCR Oncology — Arroyo Grande, California
- Mills-Peninsula Medical Center — Burlingame, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Health System - Encinitas — Encinitas, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Cedars Sinai Medical Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other …
Sponsor: Pfizer
NCT ID: NCT07227415
Sites in California: - City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- City of Hope Investigational Drug Services (IDS) — Duarte, California
- City of Hope Investigational Drug Services (IDS) — Irvine, California
- City of Hope — Irvine, California
- City of Hope — Long Beach, California
Phase 1, Phase 2 Recruiting NIH
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first starte…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05896839
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
- Keck Medicine of USC Koreatown — Los Angeles, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in California: - John Wayne Cancer Institute (JWCI) — Santa Monica, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- Lucile Packard Children's Hospital Stanford University — Palo Alto, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05985161
Sites in California: - Children's Hospital of Los Angeles (Data Collection Only) — Los Angeles, California
- Stanford Medicine Children's Health (Data Collection Only) — Palo Alto, California
Phase 2 Recruiting NIH
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby t…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04981509
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
Phase 1, Phase 2 Recruiting Industry
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage.…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06413680
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
- University of California San Francisco (UCSF) — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in California: - Community Cancer Institute — Clovis, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in California: - UCSD Moores Cancer Center — La Jolla, California
- UCLA Medical Center — Los Angeles, California
Phase 2 Recruiting Industry
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
NCT ID: NCT06281678
Sites in California: - University of California, San Francisco (UCSF) — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibi…
Sponsor: Medicenna Therapeutics, Inc.
NCT ID: NCT05086692
Sites in California: - Sharp Memorial Hospital — San Diego, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Providence Saint John's Health Center — Santa Monica, California
Phase 1, Phase 2 Recruiting Academic/Other
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will …
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04901702
Sites in California: - Lucille Packard Children's Hospital Stanford — Palo Alto, California
Phase 1, Phase 2 Recruiting Industry
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experi…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07049926
Sites in California: - UCSF Medical Center at Mission Bay ( Site 5008) — San Francisco, California
Phase 2 Recruiting Academic/Other
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or …
Sponsor: Vanderbilt-Ingram Cancer Center
NCT ID: NCT05361720
Sites in California: - City of Hope National Medical Center — Duarte, California
- Chao Family Comprehensive Cancer Center — Orange, California
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in California: - Precision NextGen Oncology — Beverly Hills, California
- OPN Healthcare, Inc — Glendale, California
- University of Southern California — Los Angeles, California
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in California: - Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California